Guideline for Antibiotic Use in Acute Infectious Gastroenteritis

1. Situations Where Antibiotics Are Not Required

• Non‑bloody, non‑febrile diarrhea should be managed with watchful waiting and symptomatic therapy only (Clinical Microbiology and Infection, 2024) 1.
• Immunocompetent patients with non‑typhoidal Salmonella infection and no risk factors do not need antimicrobial therapy (Clinical Microbiology and Infection, 2024) 2.
• Suspected enterohemorrhagic E. coli (EHEC) infections should not receive antibiotics because of the heightened risk of hemolytic‑uremic syndrome (Clinical Microbiology and Infection, 2024) 2.

2. Indications for Antibiotic Therapy

• Bloody diarrhea (dysentery) warrants antimicrobial treatment (Journal of Travel Medicine, 2017) 3.
• Fever accompanying diarrhea is an indication for antibiotics (Journal of Travel Medicine, 2017) 3.
• Confirmed Shigella infection requires therapy (Clinical Microbiology and Infection, 2024) 2.
• Cholera infection should be treated with antibiotics (Clinical Microbiology and Infection, 2024) 4.
• Severe Campylobacter infection, if treated within 72 hours of symptom onset, benefits from antibiotics (Journal of Travel Medicine, 2017) 3.
• High‑risk patients (age < 6 months or > 50 years, immunocompromised, prosthetic devices, valvular heart disease, severe atherosclerosis, malignancy) should receive antibiotics (Clinical Microbiology and Infection, 2024) 2.
• Traveler’s diarrhea causing incapacitation is an indication for antimicrobial therapy (Journal of Travel Medicine, 2017) 3.

3. First‑Line Antibiotic Recommendations

3.1 Dysentery or Febrile Diarrhea

• Azithromycin is the preferred first‑line agent (Journal of Travel Medicine, 2017) 3.
  
  • Dosing: single 1 g oral dose or 500 mg once daily for 3 days (Journal of Travel Medicine, 2017) 5.
  • Rationale: Superior efficacy in regions with high fluoroquinolone‑resistant Campylobacter (>90 % resistance in Thailand) (Journal of Travel Medicine, 2017) 3.
  • Spectrum: Active against Shigella, Campylobacter, enteroinvasive E. coli, and other invasive pathogens (Journal of Travel Medicine, 2017) 5.
  • Safety: Well‑tolerated; nausea in ~3 % and vomiting in < 1 % of patients (Journal of Travel Medicine, 2017) 3.

3.2 Non‑Dysenteric Watery Diarrhea

• Ciprofloxacin remains an option when local susceptibility is documented (Clinical Microbiology and Infection, 2024) 1.
  
  • Dosing: single dose or a 3‑day course (Journal of Travel Medicine, 2017) 3.
  • Guideline: 2024 WHO Expert Committee selected ciprofloxacin as first‑choice for invasive bacterial diarrhea due to concerns about sulfamethoxazole‑trimethoprim resistance (Clinical Microbiology and Infection, 2024) 6.
  • Resistance threshold: Avoid ciprofloxacin if local E. coli susceptibility is < 90 % (Clinical Infectious Diseases, 2010) 7.
• Rifaximin (three times daily for 3 days) shows equivalent efficacy to fluoroquinolones and azithromycin for non‑invasive watery diarrhea (Journal of Travel Medicine, 2017) 3.

4. Pathogen‑Specific Recommendations

4.1 Shigella

• First‑line: Azithromycin (Journal of Travel Medicine, 2017) 3.
• Alternative: Ceftriaxone (β‑lactam) is more effective than fluoroquinolones for confirmed Shigella (Clinical Microbiology and Infection, 2024) 8.
• Avoid: Sulfamethoxazole‑trimethoprim due to widespread resistance (Clinical Microbiology and Infection, 2024) 1.

4.2 Cholera

• First‑line: Azithromycin (single dose superior to ciprofloxacin, reducing diarrhea duration by > 32 hours) (Clinical Microbiology and Infection, 2024) 8.
• Second‑line: Doxycycline or tetracycline (Clinical Microbiology and Infection, 2024) 2.
• Avoid: Sulfamethoxazole‑trimethoprim (less effective than doxycycline) (Clinical Microbiology and Infection, 2024) 4.

4.3 Severe Campylobacter

• Azithromycin must be administered within 72 hours of symptom onset for optimal efficacy (Journal of Travel Medicine, 2017) 3.
• Fluoroquinolones have high failure rates because of prevalent resistance (Journal of Travel Medicine, 2017) 5.

4.4 Non‑Typhoidal Salmonella (when treatment indicated)

• Severe infection or high‑risk patients: Ceftriaxone or ciprofloxacin (Clinical Microbiology and Infection, 2024) 1.
• Alternative: Azithromycin (Clinical Microbiology and Infection, 2024) 2.

4.5 Clostridioides difficile

• Therapy: Oral metronidazole or oral vancomycin (Clinical Microbiology and Infection, 2024) 4.

5. Safety, Toxicity, and Resistance Considerations

• Fluoroquinolone toxicity: FDA has issued strengthened warnings; reserve fluoroquinolones for cases where no suitable alternatives exist (Clinical Microbiology and Infection, 2024) 8.
• Local resistance surveillance: Antibiotic selection must be guided by regional resistance patterns, especially E. coli quinolone resistance and Bacteroides fragilis anaerobic coverage (Clinical Infectious Diseases, 2010) 7.
• Treatment duration: Single‑dose or 3‑day regimens are equally effective for most indications and improve patient adherence (Journal of Travel Medicine, 2017) 5.

Antibiotic Stewardship in Acute Bacterial Gastroenteritis

When to Withhold Antibiotics

• In healthy adults living in developed countries, routine empirical antibiotics for uncomplicated acute gastroenteritis are not recommended because they contribute to antimicrobial resistance. 9

Combination Therapy

• Adding loperamide to azithromycin in patients with non‑dysenteric or mildly febrile dysentery accelerates symptom resolution compared with azithromycin alone. [9][10]

Resistance‑Driven Recommendations

• Macrolides (e.g., erythromycin), penicillins (e.g., ampicillin), and tetracyclines (e.g., doxycycline) are no longer advised for empirical therapy of acute bacterial gastroenteritis due to widespread resistance among common pathogens. [9][10]
• Sulfamethoxazole‑trimethoprim (co‑trimoxazole) has lost reliability for empirical use because increasing resistance limits its effectiveness. [9][10]

Guidance on Fluoroquinolone Use

• Ciprofloxacin should be avoided for non‑dysenteric watery diarrhea when local Escherichia coli susceptibility to fluoroquinolones is below 90 %; selection must be based on regional susceptibility data. 11
• Fluoroquinolones exhibit high failure rates for severe Campylobacter infection because of prevalent resistance, making them unsuitable as first‑line agents in this context. [9][10]

Travelers’ Diarrhea Treatment Duration

• Short antibiotic courses (single dose up to 2 days) for travelers’ diarrhea achieve clinical remission within 1–3 days, improving adherence without compromising efficacy. [9][10]

Importance of Local Resistance Surveillance

• Antibiotic choice for acute bacterial gastroenteritis should be guided by up‑to‑date regional resistance patterns, especially the prevalence of quinolone‑resistant E. coli. 11

Antibiotic Recommendations for Acute Bacterial Diarrhea

First‑Line Empiric Therapy

• Ciprofloxacin (a quinolone) is recommended as the first‑line empirical agent for dysentery or infectious diarrhea when local quinolone resistance remains low. 12
• Azithromycin is the preferred first‑line agent for dysentery or febrile diarrhea in regions with high fluoroquinolone‑resistant Campylobacter (e.g., >90 % resistance in parts of Southeast Asia). 13
• Rifaximin may be used as an alternative for non‑bloody, non‑febrile watery diarrhea when a non‑invasive pathogen is suspected. 13

Position of Cotrimoxazole

• Cotrimoxazole is no longer a first‑line option for acute bacterial diarrhea because rising bacterial resistance has markedly reduced its effectiveness; it may be considered a second‑line choice only when susceptibility is documented or when first‑line agents are unavailable or contraindicated. 12
• For traveler’s diarrhea, cotrimoxazole is placed after quinolones as a second‑line option. 12
• Cotrimoxazole can be used for secretory diarrheal illnesses when the causative pathogen is identified and proven susceptible to the drug. 12

Azithromycin Specific Guidance

• Azithromycin (single 1 g dose or 500 mg daily for 3 days) shows superior efficacy for bloody or febrile diarrhea in settings with high fluoroquinolone resistance, covering Shigella, Campylobacter, invasive E. coli and other invasive pathogens. 13
• In Southeast Asia and India, azithromycin should be employed empirically as the first‑line therapy to ensure coverage of fluoroquinolone‑resistant Campylobacter. 13

Resistance Trends

• Widespread resistance has rendered macrolide (erythromycin), penicillin (ampicillin) and tetracycline (doxycycline) unsuitable for empirical treatment of acute bacterial diarrhea. 12
• Increasing resistance to sulfamethoxazole‑trimethoprim (cotrimoxazole) limits its reliability for empirical use. (derived from cited sources) 12

Adverse Effects of Cotrimoxazole

• Skin reactions and photosensitivity are recognized adverse events associated with cotrimoxazole (and related nitrofuran compounds). 12
• Secondary antibiotic‑associated colitis/diarrhea can occur following cotrimoxazole therapy. 12

Practical Treatment Considerations

• Combining loperamide with cotrimoxazole can hasten clinical remission in both non‑dysenteric and mild febrile dysentery. 12
• A single‑dose regimen or a short 3‑day course of the chosen antibiotic provides comparable efficacy for most acute bacterial diarrheal indications and improves patient adherence. 13

Summary Statement

• Modern guidelines prioritize azithromycin and fluoroquinolones as first‑line agents for acute bacterial diarrhea; cotrimoxazole retains a limited, second‑line role only when susceptibility is confirmed and resistance rates are low. [12][13]